From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Other content in this Stream
Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management
Prometic announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc.
Prometic retains investment bank for strategic transactions
Prometic announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation.
Annual Information Form 2017
Prometic Annual Information Form 2017
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Corporate Governance and Nominating Committee Charter 2017
Board of Directors Charter 2017
Audit, Risk and Finance Committee Charter 2017
Chairman Mandate 2018
Code of Ethics and Business Conduct 2017
Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment